The Clinical-Translational Core provides an infrastructure for patient-oriented research by streamlining regulatory and compliance processes, obtaining and storing high-quality samples linked to extensive clinical phenotypic information, offering expert consultation in the design and implementation of patient-oriented trials, and supplying statistical expertise for application of innovative analytic methods in translational and patient-oriented research. The Core was established to facilitate the performance of patient oriented research to Core members. The Clinical-Translational Core has been extremely effective in accomplishing its goals, generating a large number of original publications and establishing numerous collaborations with facilities and investigators that have increased or supplemented the available services (e.g. the Office of Research Services of the Yale Center for Clinical Investigation that has been assisting Liver Center investigators, at no cost, in preparing and submitting new research projects), and provide additional sources of support for Core activities (support for inpatient data collection from the National Consortium for the Study of Endstage Liver Disease) as well as increasing the number of core members. The Clinical-Translational Core offers the following specific activities and services, plus associated training and technical support: 1) a resource (Clinical Core Coordinator) that facilitates regulatory processes (obtaining and maintaining IRB approval for the performance of patient-oriented research), 2) clinical registries consisting mainly of a patient (1,875 unique patients), and a sample registry (blood samples from 939 unique patients), as well as disease-specific databases that have been collected by different center investigators over the years, 3) statistical support, including study design and implementation and data analysis.
The primary focus of the Yale Liver Center is the study of liver structure, function, and disease. The Clinical-Translational Core plays a key role in this endeavor by facilitating the performance of translational patient-oriented research.
|Tran, Melanie; Lee, Sang-Min; Shin, Dong-Ju et al. (2017) Loss of miR-141/200c ameliorates hepatic steatosis and inflammation by reprogramming multiple signaling pathways in NASH. JCI Insight 2:|
|Cai, Shi-Ying; Boyer, James L (2017) Studies on the mechanisms of bile acid initiated hepatic inflammation in cholestatic liver injury. Inflamm Cell Signal 4:|
|Yang, An-Ming; Inamine, Tatsuo; Hochrath, Katrin et al. (2017) Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest 127:2829-2841|
|Park, Jin-Kyu; Shao, Mingjie; Kim, Moon Young et al. (2017) An endoplasmic reticulum protein, Nogo-B, facilitates alcoholic liver disease through regulation of kupffer cell polarization. Hepatology 65:1720-1734|
|Yu, Dongke; Zhang, Han; Lionarons, Daniel A et al. (2017) Na+-taurocholate cotransporting polypeptide (NTCP/SLC10A1) ortholog in the marine skate Leucoraja erinacea is not a physiological bile salt transporter. Am J Physiol Regul Integr Comp Physiol 312:R477-R484|
|Jangouk, Parastoo; Turco, Laura; De Oliveira, Ana et al. (2017) Validating, deconstructing and refining Baveno criteria for ruling out high-risk varices in patients with compensated cirrhosis. Liver Int 37:1177-1183|
|Assis, David N; Abdelghany, Osama; Cai, Shi-Ying et al. (2017) Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. J Clin Gastroenterol 51:e11-e16|
|Yu, Ai-Ming; Ingelman-Sundberg, Magnus; Cherrington, Nathan J et al. (2017) Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). Acta Pharm Sin B 7:241-248|
|Tran, Melanie; Wang, Li (2017) Preserving LXR by inhibiting T39: A step closer to treating atherosclerosis and steatohepatitis? Hepatology 65:741-744|
|Feriod, Colleen N; Oliveira, Andre Gustavo; Guerra, Mateus T et al. (2017) Hepatic Inositol 1,4,5 Trisphosphate Receptor Type 1 Mediates Fatty Liver. Hepatol Commun 1:23-35|
Showing the most recent 10 out of 705 publications